SystImmune
Subsidiary of Sichuan Baili Pharmaceutical (688506)
Assets
(2 total)
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
26 February 2026Topline resultIzalontamab brengitecanPhase III BL-B01D1-307 interim topline: iza-bren met dual primary endpoints (PFS and OS) in TNBC
CN · Sichuan Biokin Pharmaceutical (SystImmune parent) · Source ↗
Financial reports
No financial reports recorded.